MCC-950

• Background :

  MCC-950 was originally found to act as a cytokine release inhibitory drug (CRID), arresting activated monocytes and preventing activation of caspase-11. Discovered to be a novel inhibitor of the NLRP3 and AIM2 inflammasomes2. Blocks canonical and noncanonical NLRP3 activation at nanomolar concentrations3. Inhibits interleukin 1β (IL-1β) secretion in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (an MS disease model) 3. Disrupts the interaction between AIM2 and ASC in a reconstituted cell-free inflammasome4. A valuable new tool for exploring the pathophysiology of NLRP3.

• Conjugation :

  Unconjugated

• Buffer :

  White solid

• Storage Conditions :

  -20°C